Pfizer Booster Lot Numbers with the Most Reported Deaths | VAERS Data

Part 4 of the Vaccine Lot Numbers Examined

🎧 ▶️ Press the play button below to listen.

Introduction

This is the fourth article in our VAERS Data Series, following our analyses of original Pfizer, original Moderna, and Moderna bivalent booster lots. Here, we examine Pfizer bivalent boosters (product code COVID-19-2), which began distribution in late 2022.

The data presented here is current as of April 24, 2026, drawn directly from the U.S. Vaccine Adverse Event Reporting System (VAERS) — a national passive surveillance database co-managed by the CDC and FDA.

---

Striking Finding: Pfizer Booster Death Reports Nearly Double Moderna Booster Reports

Vaccine Product	Total Death Reports (VAERS)	Time Period
Pfizer Bivalent Booster	203	2022–2024
Moderna Bivalent Booster	112	2022–2024

This difference is notable. However, VAERS alone cannot tell us why. Possible explanations include:

Possible Factor	Why It Matters
Higher usage	Pfizer administered ~60-70% of U.S. booster doses; more doses naturally produce more reports
Different formulations	Pfizer (30µg) vs. Moderna (50µg) bivalent boosters have different mRNA content
Population differences	Some facilities or states preferentially used one brand, leading to different risk profiles
Reporting bias	Pfizer’s higher visibility may have led to more VAERS submissions

What this does NOT mean: The difference does not prove Pfizer boosters are less safe than Moderna boosters. VAERS lacks denominators (doses administered per lot), cannot separate coincidental deaths, and suffers from reporting fatigue and bias.

---

Important Context: Why Booster Death Reports Are Lower Than Original Series

Vaccine Type	Total Death Reports (VAERS)	Key Population
Original Pfizer (monovalent)	8,452	Elderly, nursing home residents, highest-risk
Pfizer Bivalent Booster	203	Younger, healthier, prior immunity

The most vulnerable individuals were vaccinated in 2020–2021. By the time bivalent boosters rolled out in late 2022, many high-risk individuals had already died, and the remaining population was generally younger and healthier.

This does not mean boosters are safer. It means the population receiving boosters had a much lower baseline risk of death. Comparing raw death counts between original series and boosters is invalid without adjusting for age, health status, and time at risk.

---

Summary of Key Caveats

What these numbers ARE	What these numbers ARE NOT
Reports of death after Pfizer booster vaccination	Proof of death because of the booster
Useful for generating hypotheses	Useful for determining safety or risk
A reflection of reported volume	A reflection of actual death rates
Known to capture fewer than 1% of events	A complete or accurate count

---

The Attribution Problem: Booster vs. Original Series

When a person who received:

• Original Pfizer primary series (2020–2021)
• Pfizer bivalent booster (2022 or later)

Experiences a serious adverse event or death, VAERS typically records only the most recent lot (the booster). However, the event could be related to:

• The booster itself
• The original primary series (with delayed onset)
• An interaction between doses
• Purely coincidental background illness

VAERS cannot distinguish between these possibilities. This is especially important for booster data, because nearly everyone receiving a booster also received at least two prior doses.

---

The Lazarus Report: Underreporting Still Applies

As noted in our previous articles, the Lazarus Report (AHRQ Grant No. R18HS017045) found that:

“Fewer than 1% of vaccine adverse events are reported to VAERS.”

This means the 203 death reports in this dataset likely represent only a small fraction of actual deaths that occurred after Pfizer booster vaccination. The true number is unknown but almost certainly higher.

---

Reporting Fatigue: A Critical Additional Factor

By the time Pfizer bivalent boosters rolled out in late 2022, the U.S. had been vaccinating against COVID-19 for nearly two years. Millions of doses had been administered. The media frenzy over vaccine side effects had subsided. And people — including healthcare providers — were simply tired of reporting.

Why Reporting Fatigue Matters for Booster Data

Factor	Impact on VAERS Reporting
Pandemic fatigue	By 2022, many people were exhausted and stopped filing reports
Provider burnout	Healthcare workers had less time for voluntary reporting
Diminished media attention	Deaths after boosters received far less news coverage
Perceived “old news”	Reporters and the public assumed vaccine safety was already settled

What This Means for the Numbers

Even if Pfizer boosters had the exact same underlying risk as the original Pfizer series, we would expect to see far fewer VAERS reports simply because fewer people would have stopped reporting.

In other words:

The drop from 8,452 death reports (original Pfizer) to 203 death reports (Pfizer boosters) is likely due to a combination of:

1. A healthier vaccine recipient population (fewer background deaths)
2. Reporting fatigue (fewer reports filed)
3. Possibly, but not necessarily, a safer vaccine

VAERS cannot tell us which factor is most important.

---

Top 100 Pfizer Bivalent Booster Lots by Total VAERS Death Reports

The table below ranks Pfizer bivalent booster lots by the total number of death reports in VAERS (all reports combined). These are raw, unverified counts. See the limitations above before drawing any conclusions.

Rank	Vaccine Lot	Total Death Reports
1	GH9693	17
2	GH9703	14
3	GH9694	12
4	GH9702	11
5	GJ5342	11
6	GJ3275	8
7	GJ6665	8
8	GJ3277	7
9	No lot numbers reported	24
10	GJ3274	6
11	GL0446	6
12	GJ6739	5
13	GH9697	3
14	GJ2524	3
15	GJ3268	3
16	GJ6742	3
17	GJ6796	3
18	GL0447	3
19	330308D	2
20	6H9693	2
21	6H9703	2
22	EW0158	2
23	EW0169	2
24	FK9894	2
25	FM7553	2
26	FM9992	2
27	GH9664	2
28	GJ3270	2
29	GJ6738	2
30	GJ6743	2
31	GK1337	2
32	HD9876	2
33	HG7557	2
34	HH3221	2
35	030G22B	1
36	065H22A	1
37	207H232A	1
38	33030BD	1
39	348360	1
40	6J3277	1
41	649693	1
42	EN6200	1
43	ER8727	1
44	EW0153	1
45	FC3183	1
46	FE3590	1
47	FF2593	1
48	FX5095	1
49	G=GK0928	1
50	G5327S	1
51	GH0446	1
52	GH89703	1
53	GJ6739 (duplicate)	1
54	GJ6743 (duplicate)	1
55	GK0923	1
56	GL0087	1
57	HD9835	1
58	HG2649	1
59	HG4665	1
60	HH3897	1
61	HN0478	1
62	QJ3275	1
63	UNK	2
64	UNKNOWN	1

Note: Lots with identical totals are ranked alphabetically within the same count. The NONE category (missing lot number) had 24 reports. Some lots appear multiple times due to minor spelling variations in the raw data.

---

What This Table Actually Shows

If you think it shows…	The truth is…
The most dangerous Pfizer booster lots	The most widely used Pfizer booster lots (e.g., GH9693, GH9703, GH9694, GH9702, GJ5342)
A safety signal	A reporting signal (higher volume lots naturally have more reports)
That Pfizer boosters are less safe than Moderna boosters	Pfizer boosters were used more widely; VAERS lacks denominators to compare
Proof of vaccine harm	Proof that VAERS captures coincidental deaths

---

Notable Observations

1. GH9693 is the highest-ranked lot with 17 death reports — a small number compared to original Pfizer lots (which had dozens or hundreds).
2. The top 10 lots account for the majority of reports (approximately 100 of the 203 total).
3. Many lots have only 1 report — this is typical for a vaccine distributed widely across thousands of lots.
4. No Pfizer booster lot has been recalled or flagged as unsafe by the CDC or FDA based on VAERS data.
5. Reporting fatigue likely means the true number of adverse events is higher than even the underreporting rate would suggest.

---

Pfizer vs. Moderna Booster Comparison (Raw VAERS Counts)

Manufacturer	Total Death Reports (Booster)	Top Lot Deaths
Pfizer	203	GH9693 (17)
Moderna	112	AS7144B (6)

Again, this difference does NOT mean Pfizer boosters are less safe. Possible explanations include:

• Pfizer administered more booster doses overall (~60-70% of the U.S. market share)
• Different distribution patterns (some regions or facilities used one brand predominantly)
• Different bivalent formulations (Pfizer 30µg vs. Moderna 50µg)
• Reporting bias (Pfizer’s higher profile may have generated more reports)

Without dose administration data per lot, no safety comparison between manufacturers is possible from VAERS alone.

---

The Bottom Line: Lessons Continue

The COVID-19 pandemic has taught us many lessons — not all of them from mainstream medicine. This analysis of Pfizer booster data reinforces several truths:

1. Raw VAERS counts cannot be compared across time because the populations changed dramatically, and reporting fatigue reduced filing rates.
2. Pfizer booster death reports (203) are nearly double Moderna booster reports (112) — but this likely reflects higher usage, not lower safety.
3. Attribution is impossible from VAERS alone. A death after a booster may not be caused by the booster.
4. Underreporting means the true number of adverse events is higher than what VAERS captures. Reporting fatigue makes this even more pronounced for boosters.

People should look back and learn from what happened — because it can possibly happen again. Better data systems, better denominators, better reporting incentives, and better transparency are needed before the next pandemic.

---

Data Source and Methodology

• Data source: CDC WONDER VAERS database
• Query date: May 20, 2026
• Filter: Pfizer bivalent booster (COVID-19-2), U.S. reports only, symptom = DEATH
• Processing: Reports processed through April 24, 2026
• Total events: 203 unique death reports
• Aggregation: Reports summed per unique lot number; NONE (missing lot) excluded from ranking but noted separately

---

Series Overview

Article	Vaccine Type	Total Death Reports	Top Lot (Deaths)
1	Pfizer Original Monovalent	8,452	EN6201 (236)
2	Moderna Original Monovalent	8,374	012L20A (187)
3	Moderna Bivalent Booster	112	AS7144B (6)
4	Pfizer Bivalent Booster	203	GH9693 (17)

---

Don’t Get Sick!

About Dr. Jesse Santiano, MD

Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), Instagram, and Telegram.

Related:

References:

1. United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 – 04/24/2026, CDC WONDER On-line Database. Accessed at http://wonder.cdc.gov/vaers.html on May 20, 2026, 6:09:12 PM
2. Lazarus, R. (2010). Electronic Support for Public Health – Vaccine Adverse Event Reporting System (ESP: VAERS) – Final Report (Grant No. R18 HS017045). Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.

Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.

© 2018 – 2026 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases